FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  ALTSCHULLER Susan  (Last) (First) (Middle)  C/O IMMUNOGEN, INC.  830 WINTER STREET					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [ IMGN ]  3. Date of Earliest Transaction (Month/Day/Year) 05/20/2022						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  SVP AND CFO				
(Street) WALTH		tate)	02451 (Zip)					of Original Fil	·		Line	Form fi Form fi Person	led by One F	Reporting P	erson	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Transact ate	2A. Deemed Execution Date,			3. Transacti Code (Ins	4. Secur Dispose 5)	rities Acquire	ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Nature of ndirect Beneficial Ownership Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Day/\(\text{Month/Day/\(\text{V}\)}\)	ite	of Securit Underlyin	g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D) or Indirect (I) (Instr.		Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiratior Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$4.74	05/20/2022		A		41,250		05/20/2022(1)	07/20/203	Common Stock	41,250	\$0	41,250	I		
Stock Option (Right to Buy)	\$4.74	11/14/2022		A		82,500		11/14/2022 <sup>(2)</sup>	07/20/203	Common Stock	82,500	\$0	123,750	I		

## **Explanation of Responses:**

- 1. On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
- 2. On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

/s/ Renee Lentini, Attorney-in-12/27/2022 **Fact** 

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.